Human papillomavirus type 16 recombinant adenovirus vector vaccine

治疗用人乳头瘤病毒16型重组腺病毒载体疫苗

Report date: 2023/01/02 17:05:53

Base Information

Drug NameHuman papillomavirus type 16 recombinant adenovirus vector vaccine
Drug Alias NameN/A
ClassificationVaccines > Development/production technology > Recombinant vector vaccineVaccines > Biological material > Viral vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCervical Intraepithelial NeoplasiaPapillomavirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhejiang Pukang Biologic Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesZhejiang Pukang Biologic Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsCervical Intraepithelial NeoplasiaPapillomavirus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A